FDA Panel Backs Over-The-Counter Birth Control Pill
- Vote helps pave the way for first OTC birth control option
- FDA decision expected by end of summer, company says
Opill Birth Control
Source: Perrigo/APThis article is for subscribers only.
Perrigo Co.’s over-the-counter Opill gained a key recommendation from US regulatory advisers, paving the way for the birth-control pill to get clearance to be sold without a prescription.
Members of two Food and Drug Administration advisory committees voted 17-0 in support of using the progestin-only pill without a prescription, citing studies that support consumers’ ability to use the pill properly and touting its public health benefit. The agency isn’t required to follow its advisers’ recommendations, but often does.